We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+35.5%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$614M
AUM Growth
+$229M
Cap. Flow
+$94.5M
Cap. Flow %
15.38%
Top 10 Hldgs %
48.42%
Holding
129
New
38
Increased
24
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$12.3M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$9.48M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$7.95M
4
AZN icon
AstraZeneca
AZN
+$6.54M
5
NICE icon
Nice
NICE
+$5.73M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$50.1M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$10.3M
3
GILD icon
Gilead Sciences
GILD
+$6.5M
4
GSK icon
GSK
GSK
+$6.39M
5
AGN
Allergan plc
AGN
+$6.11M

Sector Composition

Rank Sector Weight
1 Healthcare 57.48%
2 Technology 4.42%
3 Communication Services 1.38%
4 Industrials 1.09%
5 Consumer Discretionary 1.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
26
Ascendis Pharma A/S
ASND
$16B
$5.3M 0.86%
263,500
+1,700
+0.6% +$28.1K
CBIO
27
Crescent Biopharma
CBIO
$537M
$5.13M 0.84%
7,181
– –
TSRO
28
DELISTED
TESARO, Inc.
TSRO
$5.01M 0.82%
+50,000
New +$4.67M
EIGR
29
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$5M 0.81%
12,452
+7,428
+148% +$3.79M
NDRM
30
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.69M 0.76%
253,513
-5,000
-2% -$86.7K
ADMS
31
DELISTED
Adamas Pharmaceuticals
ADMS
$4.43M 0.72%
270,000
– –
CHTR icon
32
Charter Communications
CHTR
$17.3B
$4.36M 0.71%
16,165
+100
+0.6% +$25.3K
TVTX icon
33
Travere Therapeutics
TVTX
$5.2B
$4.25M 0.69%
190,000
+40,000
+27% +$761K
AVXS
34
DELISTED
AveXis, Inc. Common Stock
AVXS
$4.12M 0.67%
+100,000
New +$3.8M
GWPH
35
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$4.12M 0.67%
31,000
-9,000
-23% -$860K
RNAC icon
36
Cartesian Therapeutics
RNAC
$229M
$3.99M 0.65%
+9,488
New +$3.71M
ACAD icon
37
Acadia Pharmaceuticals
ACAD
$4.43B
$3.98M 0.65%
+125,000
New +$4.24M
CLSD
38
DELISTED
Clearside Biomedical
CLSD
$3.92M 0.64%
15,073
-4,927
-25% -$603K
MGNX icon
39
MacroGenics
MGNX
$235M
$3.89M 0.63%
130,000
– –
GOOGL icon
40
Alphabet (Google) Class A
GOOGL
$4.36T
$3.87M 0.63%
96,360
+13,120
+16% +$513K
RCKT icon
41
Rocket Pharmaceuticals
RCKT
$340M
$3.81M 0.62%
100,441
+37,941
+61% +$1.19M
FIS icon
42
Fidelity National Information Services
FIS
$23.1B
$3.71M 0.6%
+48,160
New +$3.76M
ALDR
43
DELISTED
Alder Biopharmaceuticals
ALDR
$3.69M 0.6%
112,500
– –
UNP icon
44
Union Pacific
UNP
$174B
$3.63M 0.59%
+37,275
New +$3.49M
V icon
45
Visa
V
$684B
$3.54M 0.58%
42,791
+4,825
+13% +$386K
ORBK
46
DELISTED
Orbotech Ltd
ORBK
$3.44M 0.56%
116,102
+31,892
+38% +$904K
FOMX
47
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.17M 0.52%
342,000
– –
APD icon
48
Air Products & Chemicals
APD
$65.7B
$3.16M 0.52%
+22,750
New +$3.15M
FPRX
49
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$3.15M 0.51%
60,000
– –
GNCA
50
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.12M 0.51%
76,159
-12,500
-14% -$490K
1
2
3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2016 Portfolio in Review

As of Q3 2016, Sphera Funds Management held 129 positions worth $614M, up 59% from $385M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Sphera Funds Management deployed $94.5M of net new capital in Q3 2016, opening 38 new positions and adding to 24 existing holdings. Its largest new stake was Sarepta Therapeutics: 263,047 shares worth $16.2M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 77% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Shire pic, an estimated $50.1M trimmed.

  • Sphera Funds Management's largest Q3 2016 buy was Sarepta Therapeutics: 263,047 shares worth $16.2M.
  • Sphera Funds Management added most to Merck in Q3 2016, an estimated $12.3M increase.
  • Sphera Funds Management's biggest Q3 2016 reduction was Shire pic, cutting an estimated $50.1M.
  • Sphera Funds Management fully exited GSK in Q3 2016, selling an estimated $6.39M.
  • Sphera Funds Management's ten largest holdings make up 48% of its $614M portfolio in Q3 2016.
  • Sphera Funds Management opened 38 new positions and closed 23 in Q3 2016.
  • Sphera Funds Management's portfolio value rose 59% quarter-over-quarter to $614M.

Based on Sphera Funds Management's 13F filing for Q3 2016, filed 14 Nov 2016.